SCHEMBL5159730

SCHEMBL5159730

CC(Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 1.00
KDM4E B2RXH2 2/20 1.00
MAPT P10636 2/20 1.00
APAF1 O14727 1/20 1.00
RECQL P46063 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
SMN1; SMN2 Q16637 1/20 0.70
MEN1 O00255 1/20 0.68
LMNA P02545 1/20 0.68
MPO P05164 1/20 0.68
TSHR P16473 1/20 0.68
BLM P54132 1/20 0.68
PMP22 Q01453 1/20 0.68
KMT2A Q03164 1/20 0.68
HIF1A Q16665 1/20 0.68
ACE P12821 2/20 0.63
ADRB1 P08588 1/20 0.62
HTR1A P08908 1/20 0.62
ADRA2A P08913 1/20 0.62
SLC6A2 P23975 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9880194 1.00 POLB (1.00) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL9880193 1.00 POLB (1.00) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL13971370 0.88 POLB (0.78) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL17326082 0.88 POLB (0.78) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL9336530 0.87 MAPT (0.76) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL4666382 0.86 POLB (0.76) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL8266826 0.86 POLB (0.76) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL9449541 0.85 SMN1; SMN2 (0.77) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL20425214 0.85 KDM4E (0.73) POLBKDM4EMAPTAPAF1RECQL
SCHEMBL20425212 0.85 KDM4E (0.73) POLBKDM4EMAPTAPAF1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1217884-B1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2007-02-21 EP claimed
US-6897065-B1 Method for maturation of conifer somatic embryos WOODY PLANT BIOTECH APS (DK) 2005-05-24 US claimed
EP-1217884-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS Woody Plant Biotech APS (DK) 2002-07-03 EP claimed
WO-2001020972-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2001-03-29 WO claimed
US-20230277454-A1 NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER MASSACHUSETTS EYE AND EAR INFIRMARY 2023-09-07 US disclosed
US-11739326-B2 RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2023-08-29 US disclosed
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING MAGICMED INDUSTRIES INC. (CA) 2023-07-13 US disclosed
US-11583497-B2 Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2023-02-21 US disclosed
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-31 US disclosed
US-20220184109-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS MASSACHUSETTS EYE AND EAR INFIRMARY 2022-06-16 US disclosed
US-20220160849-A1 CANCER VACCINE FORMULATION MIE UNIVERSITY (JP) 2022-05-26 US disclosed
US-11229662-B2 Compositions and methods for the treatment of aberrant angiogenesis THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) 2022-01-25 US disclosed
US-20150191517-A1 NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF PURDUE PHARMA L.P. (US) 2015-07-09 US disclosed
WO-2012066549-A1 DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-05-24 WO disclosed
US-20120108529-A1 PROTEASE INHIBITORS AMPLYX PHARMACEUTICALS, INC. 2012-05-03 US disclosed
EP-1415986-B1 SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS BANYU PHARMA CO LTD (JP) 2009-04-08 EP disclosed
WO-2008106619-A2 INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2008-09-04 WO disclosed
EP-1217884-B1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2007-02-21 EP disclosed
EP-1217884-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS Woody Plant Biotech APS (DK) 2002-07-03 EP disclosed
WO-2001020972-A1 METHOD FOR MATURATION OF CONIFER SOMATIC EMBRYOS WOODY PLANT BIOTECH APS (DK) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11229662-B2 Compositions and methods for the treatment of aberrant angiogenesis VEGFA, PGF, FLT4 POLB 2595/4885KDM4E 4412/4885MAPT 1642/4885
US-20230219888-A1 PRENYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING AANAT, ACAT2, PCYT1A POLB 1233/4885KDM4E 3448/4885MAPT 2331/4885
US-20220160849-A1 CANCER VACCINE FORMULATION CD44, TP53, MUC1 POLB 4789/4885KDM4E 2970/4885MAPT 3086/4885
US-11739326-B2 RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition RUNX1, CXCL12, MITF POLB 1058/4885KDM4E 1672/4885MAPT 2925/4885
US-20220184109-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS VEGFA, PGF, FLT4 POLB 2595/4885KDM4E 4412/4885MAPT 1642/4885
US-20120108529-A1 PROTEASE INHIBITORS SERPINB1, PREP, DNPEP POLB 1065/4885KDM4E 858/4885MAPT 1811/4885
US-20150191517-A1 NOVEL SODIUM CHANNEL BLOCKING PEPTIDES AND THE USE THEREOF SCN7A, SCN2A, SCN5A POLB 4536/4885KDM4E 3499/4885MAPT 4023/4885
US-20230277454-A1 NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVER RUNX1, CBFB, IKZF1 POLB 861/4885KDM4E 442/4885MAPT 1318/4885
US-11583497-B2 Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery RUNX1, CBFB, IKZF1 POLB 907/4885KDM4E 470/4885MAPT 1348/4885
US-11564971-B2 Hyaluronic acid derivative having amino acid and steryl group introduced thereinto CD44, DAO, FUT6 POLB 4801/4885KDM4E 3563/4885MAPT 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.